Cipla Limited — Paclitaxel Exporter Profile
Indian Pharmaceutical Exporter · #11 for Paclitaxel · $950.0K export value · DGFT Verified
Cipla Limited is the #11 Indian exporter of Paclitaxel with $950.0K in export value and 19 verified shipments. Cipla Limited holds a 1.1% market share in Paclitaxel exports across 5 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Paclitaxel Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Paclitaxel?
| Country | Value | Shipments | Share |
|---|---|---|---|
| SOUTH AFRICA | $232.3K | 7 | 33.9% |
| AUSTRALIA | $152.0K | 5 | 22.2% |
| MOROCCO | $150.0K | 3 | 21.9% |
| TURKEY | $150.0K | 3 | 21.9% |
| UNITED STATES | $1.1K | 1 | 0.2% |
Cipla Limited exports Paclitaxel to 5 countries. The largest destination is SOUTH AFRICA accounting for 33.9% of Cipla Limited's Paclitaxel shipments, followed by AUSTRALIA (22.2%) and MOROCCO (21.9%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Paclitaxel from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| MEDPRO PHARMACEUTICA (PTY) LTD, | SOUTH AFRICA | $210.3K | 6 |
| COOPER PHARMA | MOROCCO | $150.0K | 3 |
| APOTEX AUSTRALIA | AUSTRALIA | $150.0K | 3 |
| BMED INTERNATIONAL BUSINESS COMPANY | TURKEY | $150.0K | 3 |
| MEDPRO PHARMACEUTICA (PTY) LTD | SOUTH AFRICA | $21.9K | 1 |
| ARROTEX PHARMACEUTICALS PTY | AUSTRALIA | $2.0K | 2 |
| NANOIMAGING SERVICES , INC | UNITED STATES | $1.1K | 1 |
Cipla Limited supplies Paclitaxel to 7 buyers globally. The largest buyer is MEDPRO PHARMACEUTICA (PTY) LTD, (SOUTH AFRICA), followed by COOPER PHARMA (MOROCCO) and APOTEX AUSTRALIA (AUSTRALIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Paclitaxel Export Value and How Much Does Cipla Limited Contribute?
India exported $61.4M worth of Paclitaxel through 4,928 shipments from 319 suppliers to 142 countries, serving 959 buyers globally. Cipla Limited contributes $950.0K to this total, accounting for 1.1% of India's Paclitaxel exports. Cipla Limited ships Paclitaxel to 5 countries through 7 buyers.
What Is the Average Shipment Value for Cipla Limited's Paclitaxel Exports?
Cipla Limited's average Paclitaxel shipment value is $50.0K per consignment, based on 19 shipments totaling $950.0K. The largest destination is SOUTH AFRICA (33.9% of Cipla Limited's Paclitaxel exports).
How Does Cipla Limited Compare to Other Indian Paclitaxel Exporters?
Cipla Limited ranks #11 among 319 Indian Paclitaxel exporters with a 1.1% market share. The top 3 exporters are FRESENIUS KABI ONCOLOGY LIMITED ($25.1M), MSN LABORATORIES PRIVATE LIMITED ($6.9M), INTAS PHARMACEUTICALS LIMITED ($5.9M). Cipla Limited processed 19 shipments to 5 destination countries.
What Paclitaxel Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| CIPLA PACLITAXEL 100MG/16.7ML (PACLITAXE | $195.4K | 5 |
| CIPLA PACLITAXEL (PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION(ALBUMIN-BOUND)100MG PER VIAL)[P/S:1X50ML] | $100.0K | 2 |
| PACLITAXEL COOPER 30MG/5ML(PACLITAXEL IN | $50.0K | 1 |
| PACLITAXEL COOPER 100 MG 16 7 ML PACLITAXEL INJECTION LIQUID 6 MG ML | $50.0K | 1 |
| PACLITAXEL COOPER 100 MG 16 7 ML PACLITA | $50.0K | 1 |
| NAB-PACLITAXEL JUNO 100MG POWDER FOR INJECTION (NANOPARTICLE ALBUMIN BOUND PACLITAXEL100MG PER VIAL)(3656PACKS)(1X50ML) | $50.0K | 1 |
| NAB-PACLITAXEL JUNO 100MG POWDER FOR INJECTION(NANOPARTICLE ALBUMIN BOUND PACLITAXEL 100MG PER VIAL)(3610PACKS)(1X50ML) | $50.0K | 1 |
| NAB-PACLITAXEL JUNO 100MG POWDER FORINJECTION(NANOPARTICLE ALBUMIN BOUND PACLITAXEL 100MG PER VIAL)(3703 PACKS)(1X50ML) | $50.0K | 1 |
| CIPLA PACLITAXEL (PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION(ALBUMIN-BOUND),100MG PER VIAL) (1X50 ML) | $50.0K | 1 |
| CIPLA PACLITAXEL 30MG/5ML (PACLITAXEL IN | $36.9K | 2 |
Cipla Limited exports 12 distinct Paclitaxel formulations including tablets, capsules, syrups, and combination drugs. The top formulation is CIPLA PACLITAXEL 100MG/16.7ML (PACLITAXE with 5 shipments worth $195.4K.
Regulatory Requirements: Exporting Paclitaxel to Key Markets
What Cipla Limited must comply with to export Paclitaxel to its top destination countries
South Africa — SAHPRA
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Australia — TGA
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Cipla Limited Compare to Nearest Paclitaxel Exporters?
Exporters ranked immediately above and below #11 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 13 | SP ACCURE LABS PRIVATE LIMITED | $1.3M | 66 | 9 | $19.0K |
| 15 | NAPROD LIFE SCIENCES PRIVATE LIMITED | $1.1M | 70 | 14 | $16.1K |
| 11 | CIPLA LIMITED ★ | $950.0K | 19 | 5 | $50.0K |
| 14 | NV REMEDIES PRIVATE LIMITED | $550.0K | 11 | 3 | $50.0K |
Cipla Limited ranks #11 among 319 Indian Paclitaxel exporters. Average shipment value of $50.0K compared to the market average of $192.6K. The closest competitors by value are SP ACCURE LABS PRIVATE LIMITED and NAPROD LIFE SCIENCES PRIVATE LIMITED.
Which Indian Ports Ship Paclitaxel Exports?
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 830 | 16.8% |
| SAHAR AIR | 614 | 12.5% |
| DELHI AIR | 599 | 12.2% |
| SAHAR AIR CARGO ACC (INBOM4) | 554 | 11.2% |
| HYDERABAD AIR | 186 | 3.8% |
| AHEMDABAD AIR | 183 | 3.7% |
| Bombay Air | 172 | 3.5% |
| HYDERABAD ACC (INHYD4) | 160 | 3.2% |
Geopolitical & Trade Policy Impact on Cipla Limited's Paclitaxel Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Paclitaxel, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Paclitaxel — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Paclitaxel shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 19 individual customs records matching Cipla Limited exporting Paclitaxel, covering 12 formulations to 5 countries via 7 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 142+ countries, 959+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Paclitaxel Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Paclitaxel exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Paclitaxel Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Paclitaxel. For current shipment-level data, contact TransData Nexus.